ADAR1 Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

ADAR1 Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$201K	–	312
2026 Q1	$201K	Hold	10,000	–	–	0.01%	260
2025 Q4	$162K	Hold	10,000	–	–	0.01%	233
2025 Q3	$122K	Hold	10,000	–	–	0.01%	199
2025 Q2	$113K	Sell	10,000 -25,743	-72%	-$315K	0.02%	171
2025 Q1	$412K	Sell	35,743 -100	-0.3%	-$1.02K	0.08%	117
2024 Q4	$304K	Buy	35,843 +21,700	+153%	+$225K	0.06%	136
2024 Q3	$164K	Buy	14,143 +2,123	+18%	+$26.7K	0.03%	171
2024 Q2	$142K	Buy	12,020 +2,020	+20%	+$23.6K	0.03%	156
2024 Q1	$119K	Buy	+10,000	New	+$133K	0.03%	141

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ADAR1 Capital Management's KALV Position: Q2 2026 in Review

ADAR1 Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 10,000 shares — an estimated $201K sold.

ADAR1 Capital Management first reported a position in KALV in Q1 2024 and held it in 9 quarters. The position peaked at $412K in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

ADAR1 Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 10,000 KalVista Pharmaceuticals shares in Q2 2026, an estimated $201K.
ADAR1 Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 9 quarters.
ADAR1 Capital Management's KalVista Pharmaceuticals position peaked at $412K in Q1 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.